| Identification | Back Directory | [Name]
Benzeneacetamide, α-[(4-hydroxy-3-methoxyphenyl)methylene]-N-[2-(4-hydroxyphenyl)ethyl]-2,5-dimethoxy- | [CAS]
863193-70-8 | [Synonyms]
FLZ
Fenlean
Benzeneacetamide, α-[(4-hydroxy-3-methoxyphenyl)methylene]-N-[2-(4-hydroxyphenyl)ethyl]-2,5-dimethoxy- | [Molecular Formula]
C26H27NO6 | [MOL File]
863193-70-8.mol | [Molecular Weight]
449.5 |
| Chemical Properties | Back Directory | [Boiling point ]
710.6±60.0 °C(Predicted) | [density ]
1.245±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
8.75±0.20(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Description]
Fenlean, also known as FLZ, is currently in phase I trials by Institute of Materia Medica, Chinese Academy of Medical Science as a potential treatment of Parkinson's disease. | [Uses]
Fenlean, a natural squamosamide derivative, is a Src tyrosine kinase inhibitor. Fenlean can inhibit over-activated microglia and protect dopaminergic neurons. Fenlean can attenuate neuroinflammation in Parkinson's disease models[1][2][3]. | [References]
[1] Tai W, et, al. Inhibition of Src tyrosine kinase activity by squamosamide derivative FLZ attenuates neuroinflammation in both in vivo and in vitro Parkinson's disease models. Neuropharmacology. 2013 Dec;75:201-12. DOI:10.1016/j.neuropharm.2013.07.020
[2] Cheng LB, et, al. Squamosamide derivative FLZ protects retinal pigment epithelium cells from oxidative stress through activation of epidermal growth factor receptor (EGFR)-AKT signaling. Int J Mol Sci. 2014 Oct 17;15(10):18762-75. DOI:10.3390/ijms151018762
[3] Ye X, et, al. FLZ inhibited γ-secretase selectively and decreased Aβ mitochondrial production in APP-SH-SY5Y cells. Naunyn Schmiedebergs Arch Pharmacol. 2014 Jan;387(1):75-85. DOI:10.1007/s00210-013-0918-4 |
|
|